

| Package | Price per Dose | Price | |
|---|---|---|---|
| 360 pills | €1.91 | €858.52 €686.81 Free shipping | |
| 180 pills | €1.92 | €433.03 €346.43 Free shipping | |
| 120 pills | €1.94 | €291.20 €232.96 Free shipping | |
| 90 pills | €1.98 | €223.13 €178.50 | |
| 60 pills | €2.04 | €153.16 €122.52 | |
| 30 pills | €2.18 | €81.30 €65.04 | |
| 180 pills | €3.93 | €884.99 €707.99 Free shipping | |
| 120 pills | €3.98 | €597.55 €478.04 Free shipping | |
| 90 pills | €4.01 | €451.94 €361.55 Free shipping | |
| 60 pills | €4.05 | €304.44 €243.55 Free shipping | |
| 30 pills | €4.11 | €155.05 €124.04 | |
| 120 pills | €5.22 | €782.88 €626.30 Free shipping | |
| 90 pills | €5.29 | €595.66 €476.53 Free shipping | |
| 60 pills | €5.75 | €431.14 €344.91 Free shipping | |
| 30 pills | €5.93 | €223.13 €178.50 |
Danazol was developed in the 1960s as a synthetic derivative of ethisterone, and it remains one of the better-known anti-gonadotropic agents used to treat certain hormone-related conditions. This oral medication is a weak androgen with complex effects on the hypothalamic-pituitary-ovarian axis, helping to reduce ovarian hormone production when appropriate. In practice, it is prescribed for a focused set of conditions where lowering estrogen exposure or altering hormonal balance can alleviate symptoms.
As a pharmacologic tool, danazol exerts a dual action: it suppresses the release of pituitary hormones that stimulate the ovaries and, at the same time, introduces a degree of androgenic activity. This combination can disrupt the cycle of ectopic endometrial tissue and dampen breast tissue sensitivity in fibrocystic disease. Because of these effects, danazol is used under careful medical supervision and typically for limited periods to minimize risks.
The medication is supplied as oral capsules and is intended for adults under clinical guidance. Its use requires careful patient selection, baseline assessment, and ongoing monitoring to balance expected benefits with potential adverse effects—especially for long-term therapy or in people with liver or lipid disorders.
Endometriosis is the primary indication for danazol in many guidelines. By dampening ovarian estrogen production and altering endometrial tissue responsiveness, danazol can reduce pelvic pain, dyspareunia, and nonmenstrual bleeding associated with endometriosis. In clinical practice, response varies; some patients experience meaningful symptom relief, while others tolerate therapy only briefly due to side effects or plateauing benefit. Treatment duration is typically limited to minimize long-term risks.
Fibrocystic breast disease is another traditional use. In selected patients, danazol may lessen breast pain, tenderness, and lumpiness linked to hormonal fluctuations. The goal is symptom reduction rather than disease cure, and benefits must be weighed against androgenic effects and other safety considerations. As with endometriosis, clinicians tailor the course to the individual, with attention to changes in breast tissue, mood, and energy levels.
Beyond these core indications, danazol has historically been used in certain gynecologic disorders and as a short-term measure in select cases where reducing estrogen exposure may help with symptom severity. Because these uses are patient-specific and evolve with evidence and guidelines, they are implemented under careful medical supervision and are not considered routine first-line therapy for most conditions.
Historically, danazol has been employed for hereditary angioedema (HAE) prophylaxis in some regions, where its effect on the liver’s production of C1 esterase inhibitor can reduce the frequency and severity of attacks. When used for this purpose, the aim is to lower edema risk by modestly elevating protective protein levels, rather than to treat an acute crisis. This application is carefully weighed against potential androgenic and hepatic effects.
In practice, danazol’s role in HAE reflects a historical approach to attack prevention. It is chosen for certain patients who may not tolerate other prophylactic options or who have specific clinical circumstances. Because HAE management has advanced with newer therapies, use of danazol for this indication can vary by country and by clinician preference, and long-term safety considerations are central to decision-making.
Other off-label or less common uses have appeared in the literature or regional practice, typically grounded in specific patient histories or research settings. These uses are not universally adopted as standard care and underscore the need for individualized risk assessment, monitoring, and replacement strategies based on current guidelines and clinician judgment.
Danazol’s principal action is to suppress the pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With reduced gonadotropin signaling, the ovaries produce less estrogen, which in turn can lessen stimulation of endometrial tissue and other estrogen-driven processes. This mechanism helps alleviate symptoms such as pelvic pain in endometriosis and breast tenderness in fibrocystic disease, when patients respond to the hormonal shift.
In hereditary angioedema, danazol increases the hepatic synthesis of C1 esterase inhibitor, a key regulator of inflammatory pathways that can drive swelling attacks. While not a cure for HAE, this upregulation can translate into fewer or milder attacks for some patients. Across uses, the drug’s androgenic activity also contributes to a broader hormonal reshaping, which can influence energy, mood, and secondary physical effects.
From a pharmacologic standpoint, danazol’s activity is best understood as a targeted hormonal modulator rather than a direct corrective therapy. Its effects depend on dose, duration, and the individual’s hormonal milieu, which is why treatment plans are personalized and require ongoing clinical oversight and laboratory monitoring where appropriate.
Danazol is contraindicated in pregnancy due to teratogenic risk and potential harm to a fetus. Women of childbearing potential must use effective contraception during therapy and for a period after treatment ends. The drug can also pass into breast milk, so breastfeeding is generally discouraged during use.
Hepatic safety is a major consideration. Danazol can cause liver enzyme elevations and, in rare cases, serious liver disorders or benign hepatic adenomas. Regular liver function tests are commonly recommended during treatment, particularly for longer courses. If liver-related symptoms appear—such as right upper abdominal pain, persistent nausea, or jaundice—medical evaluation is essential.
Androgenic and metabolic effects are among the most common safety concerns. Patients may experience weight gain, acne, oily skin, hirsutism, deepening of the voice, or changes in lipid profiles. Mood changes, fatigue, and headaches can also occur. These effects often influence a patient’s willingness to continue therapy and may necessitate dose adjustments or discontinuation.
Other important considerations include potential interactions with other medicines, and the need to avoid certain therapies such as estrogens or other hormonal agents that could counteract or compound danazol’s effects. Clinicians assess individual risk factors, including liver disease, lipid disorders, and cardiovascular history, before initiating therapy and monitor accordingly throughout treatment.
14–21 days. Free from €182.27 .
5–9 days. €27.34
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
